The aim of this WG is to optimize therapeutic strategies of patients with BTC by expanding the opportunities for a precision-oncology approach, through the application of biomarker-driven strategies, development of novel approaches targeting the microenvironment and implementation of patient-centric individualization of drug choice.
Working Groups
Anna Saborowski
WG3 Leader
Angela Lamarca
WG3 co-Leader
Elene Mariamidze
WG3 co-Leader
Personalisation of treatment for patients with BTC
Tasks & Activities
To develop tissue and non-invasive biomarkers for predicting efficacy of immunotherapy.
To define novel strategies of immunotherapy personalised towards the immune phenotype of BTC subsets.
To identify the population of responders to platinum and Poly (ADP-ribose) polymerase (PARP) inhibitor therapies.
To identify mechanisms of primary and secondary resistance and to develop combinatorial targeted therapies to overcome resistance.
To define and personalise therapeutic opportunities for rare subsets of BTC, such as adenosquamous biliary cancers, intraductal papillary neoplasia of bile ducts and combined HCC/CCA.
To promote clinical trial designs that include prospective testing of biomarkers for validation.
To personalise peri-operative strategies in the management of BTC based on clinical and biological biomarkers.
To facilitate the implementation of patient-derived organoid-based individualization of BTC treatment in clinical trials.